<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969410</url>
  </required_header>
  <id_info>
    <org_study_id>P05670</org_study_id>
    <nct_id>NCT00969410</nct_id>
  </id_info>
  <brief_title>A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases</brief_title>
  <official_title>A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases (P05670)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic
      markers in subjects with advanced solid tumors who have liver metastases.

      To evaluate safety and tolerability of AV-299 administered IV in subjects with advanced solid
      tumors who have liver metastases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of AV-299 (formerly SCH 900105) on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases</measure>
    <time_frame>Screening Cycle 1: Day 1, Day 3-4: Cycle 2: Day 1 Cycle 3: Day 8-14</time_frame>
    <description>Peripheral blood analysis, liver tissue analysis, and PET</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate safety and tolerability of AV-299 (formerly SCH 900105) administered IV in subjects with advanced solid tumors who have liver metastases</measure>
    <time_frame>DLTs assessed during first 4 weeks of treatment.</time_frame>
    <description>Dose-limiting toxicities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the PK of AV-299 (formerly SCH 900105) in subjects with advanced solid tumors who have liver metastases</measure>
    <time_frame>Cycle 1: Day 1, Day 3-4 Cycle 2: Day 1 Cycle 3: Day 1, Day 8-14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To study the preliminary antineoplastic activity of AV-299 (formerly SCH 900105) in subjects with advanced solid tumors who have liver metastases</measure>
    <time_frame>Subjects will undergo disease assessment at screening (within 4 weeks prior to first dose of study drug), the Cycle 3 Day 8-14 visit, and approximately every 6 weeks thereafter.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of AV-299 (formerly SCH 900105) on gene expression patterns in peripheral blood mononuclear cells and liver biopsies in subjects with advanced solid tumors who have liver metastases</measure>
    <time_frame>Cycle 1: Day 1, Day 3-4 Cycle 3: Day 8-14:</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Malignant Solid Tumour</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>AV-299 administered IV (monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be enrolled sequentially and treated with AV-299 (formerly SCH 900105) in dose escalating cohorts. Accrual to the next cohort will occur only if &lt;= 1 out of 6 subjects experiences a dose-limiting toxicity (DLT) during the first 2 cycles. If &gt;= 2 subjects in the same dose cohort experience a DLT during the first 2 cycles, dose-escalation will be terminated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AV-299</intervention_name>
    <description>AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.</description>
    <arm_group_label>AV-299 administered IV (monotherapy)</arm_group_label>
    <other_name>Ficlatuzumab, Formerly SCH900105</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to give written informed consent and be able to adhere to dose and visit
             schedules.

          -  Diagnosis of an advanced colorectal, breast, gastric/esophageal or pancreatic cancer
             with liver metastases that are amenable to biopsy.

          -  Histological or cytological evidence of malignancy.

          -  Advanced metastatic colorectal, breast, gastric/esophageal or pancreatic cancer that
             has recurred or progressed following standard therapy or failed standard therapy; or
             for which no standard therapy currently exists, or for which subject is not a
             candidate for, or is unwilling to undergo standard therapy.

        Note: Additional tumor histologies may be eligible based on available HGF/c-Met pathway
        data and approval by the Sponsor.

          -  Disease that is currently not amenable to curative surgical intervention.

          -  Male or female and ≥ 18 years of age.

          -  ECOG performance status of 0-1.

          -  Measurable p-Met by immunohistochemistry in archived or otherwise available tumor
             sample.

          -  Female subjects of childbearing potential must have negative pregnancy test within 5
             days prior to first dose of study drug.

          -  Female subjects of childbearing potential and male subjects whose sexual partners are
             of childbearing potential must agree to abstain from sexual intercourse or to use an
             effective method of contraception during the study and for 60 days after the last dose
             of AV-299 (formerly SCH 900105). Examples of effective methods of contraception
             include oral contraceptives or double barrier methods such as condom plus spermicide
             or condom plus diaphragm.

          -  Adequate hematologic function as evidenced by Hg ≥ 9g/dL, WBC ≥ 3000 per mm3, ANC ≥
             1500 per mm3 and platelet count ≥ 100,000 per mm3.

          -  Adequate hepatic function as evidenced by a serum bilirubin level ≤ 1.5 × ULN (except
             with known Gilbert's Syndrome) and with serum AST/ALT levels ≤ 5 × ULN.

          -  Adequate renal function as evidenced by a serum creatinine level ≤ 1.5 × ULN or a
             calculated creatinine clearance &gt; 60 mL/min.

          -  Adequate coagulation function as evidenced by PTT ≤ 1.5 × ULN and INR ≤ 1.5 × ULN.

          -  Recovery from the effects of any prior surgery, radiotherapy, or systemic
             antineoplastic therapy.

          -  Subjects with abnormal liver function tests (LFTs) who have not been screened for
             Hepatitis B or C within the past 6 months prior to study enrollment, will need to be
             screened for Hepatitis B and C and can only be enrolled if the screening is negative.

        Exclusion Criteria:

          -  Women who are breast-feeding, pregnant, or intend to become pregnant.

          -  Hematologic malignancies.

          -  Any of the following within 6 months prior to administration of study drug:

          -  Myocardial infarction (MI), severe/unstable angina pectoris, coronary/peripheral
             artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident,
             transient ischemic attack or seizure disorder.

          -  Serious/symptomatic active infection, or infection requiring antibiotics, within 14
             days prior to first dose of study drug.

          -  Persistent, unresolved CTCAE v3.0 Grade 2 or higher drug-related toxicity (except
             alopecia, erectile dysfunction, hot flashes, decreased libido, and Grade 2 sensory
             peripheral neuropathy) associated with previous treatment.

          -  Inadequate recovery from any prior surgical procedure or major surgical procedure
             performed within 4 weeks prior to administration of first dose of study drug.

          -  Any other medical or psychiatric condition that, in the opinion of the investigator,
             might interfere with the subject's participation in the trial or interfere with the
             interpretation of trial results.

          -  Known Human Immunodeficiency Virus (HIV) infection or a known HIV-related malignancy.

          -  Known active hepatitis B or C.

          -  Known hypersensitivity to any of the components of SCH 900105.

          -  Known bleeding diathesis.

          -  Radiotherapy within 3 weeks prior to first study drug administration.

          -  Inability to comply with the protocol requirements, including inability to undergo
             liver biopsies.

          -  Participation in any other clinical trials involving therapeutic agents.

          -  Any medications prohibited in the study.

          -  Active alcohol or illicit drug abuse.

          -  Stem cell/bone marrow transplant within 6 months of first dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shefali Agarwal, MD</last_name>
    <role>Study Director</role>
    <affiliation>AVEO Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site 1</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2009</study_first_posted>
  <last_update_submitted>April 11, 2012</last_update_submitted>
  <last_update_submitted_qc>April 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasm metastasis</keyword>
  <keyword>Liver neoplasms</keyword>
  <keyword>Neoplastic processes</keyword>
  <keyword>Pathologic processes</keyword>
  <keyword>Digestive system neoplasms</keyword>
  <keyword>Neoplasms by site</keyword>
  <keyword>Digestive system diseases</keyword>
  <keyword>Liver diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

